Publications/Reports

2024

Chronic Hepatitis B Finite Treatment: similar and different concerns with new drug classes
Marion G Peters, Man-Fung Yuen, Norah Terrault, John Fry, Pietro Lampertico, Ed Gane, Carey Hwang, Luisa M Stamm, Mitchell Leus, Mala K Maini, Patricia Mendez, Isabelle Lonjon-Domanec, Thomas Berg, Su Wang, Poonam Mishra, Eric Donaldson, Stephanie Buchholz, Veronica Miller

Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum
Per Ljungman, Roy F. Chemaly, Fareed Khawaya, Sophie Alain, Robin Avery, Cyrus Badshah, Michael Boeckh, Martha Fournier, Aimee Hodowanec, Takashi Komatsu, Ajit P. Limaye, Oriol Manuel, Yoichiro Natori, David Navarro, Andreas Pikis, Raymund R. Razonable, Gabriel Westman, Veronica Miller, Paul D. Griffiths, and Camille N. Kotton22; for the CMV Definitions Working Group of the Transplant Associated Virus Infections Forum

Conference Report – Recommendations from the Forum for Collaborative Research Symposium on hepatitis B elimination and universal hepatitis B adult vaccination in the United States
Mitchell Leus, Mayland Treat, Veronica Miller, Arthur Reingold

A Surrogate Endpoint Based Provisional Approval Causal Roadmap
Peter B. Gilbert, James Peng, Larry Han, Theis Lange, Yun Lu, Lei Nie, Mei-Chiung Shih, Salina P. Waddy, Ken Wiley, Margot Yann, Zafar Zafari, Debashis Ghosh, Dean Follmann, Michal Juraska, Iván Díaz

Long-acting HIV Treatments: Study Design, Logistics, and Access
Murdock NA, Alajaji NE, Schaefer R, Boone CA, Campo RE, Dore GJ, Gandhi M, Gorospe JR, Gulick RM, Hodder SL, Liu J, Rhee MS, Rooney JF, Vannappagari V, Wilkin T, Miller V. Long-acting HIV Treatments: Study Design, Logistics, and Access. Open Forum Infectious Diseases 2024;11(7):ofae337.

2023

Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum
Melissa Palmer, David E. Kleiner, Zachary Goodman, Elizabeth Brunt, Mark I. Avigan, Arie Regev, Paul H. Hayashi, James H. Lewis, Ruby Mehta, Stephen A. Harrison, Massimo Siciliano, Charles A. McWherter, Raj Vuppalanchi, Cynthia Behling, Veronica Miller, Naga Chalasani, Arun J. Sanyal

Facilitating next-generation pre-exposure prophylaxis (PrEP) clinical trials using HIV recent infection assays: a consensus statement from the Forum HIV Prevention Trial Design Project
Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, Duerr A, Glidden DV, Hughes JP, Murray J, Robertson MN, Zinserling J, Lau J, Miller V. Clin Pharmacol Ther. Clin Pharmacol Ther. 2023;114:29-40.

A proposal from the Liver Forum for the management of comorbidities in nonalcoholic steatohepatitis therapeutic trials
Raluca Pais, Bertrand Cariou, Mazen Noureddin, Sven Francque, Jörn M. Schattenberg, Manal F. Abdelmalek, Gadi Lalazar 8, Sharat Varma, Julie Dietrich, Veronica Miller, Arun Sanyal, Vlad Ratziu, on behalf of the Liver Forum NAFLD-Associated Comorbidities Working Group

HDV RNA Assays: Performance characteristics, clinical utility and challenges
Heiner Wedemeyer, Mitchell Leus, Thomas R Battersby, Jeffrey Glenn, Emmanuel Gordien, Saleem Kamili, Hema Kapoor, Harald H Kessler, Oliver Lenz, Marc Lütgehetmann, Tonya Mixson-Hayden, Christian O Simon, Michael Thomson, Gabriel Westman, Veronica Miller, Norah Terrault, Pietro Lampertico

2022

Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials. Clinical Infectious Diseases. February 2022
Hannah Imlay, Paul Baum, Daniel C Brennan, Kimberly E Hanson, Michael R Hodges, Aimee C Hodowanec, Takashi E Komatsu, Per Ljungman, Veronica Miller, Yoichiro Natori, Volker Nickeleit, Jules O’Rear, Andreas Pikis, Parmjeet S Randhawa, Deirdre Sawinski, Harsharan K Singh, Gabriel Westman, Ajit P Limaye BK Disease Definitions Working Group of the Transplantation Associated Virus Infection Forum With the Forum for Collaborative Research

Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles. Orphanet Journal of Rare Diseases. May 2022
Kelley M Kidwell, Satrajit Roychoudhury, Barbara Wendelberger, John Scott, Tara Moroz, Shaoming Yin, Madhurima Majumder, John Zhong, Raymond A Huml, Veronica Miller

Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection. Journal of Hepatology. August 2022
Adam J. Gehring, Patricia Mendez, Kirsten Richter, Hildegund Ertl, Eric F. Donaldson, Poonam Mishra, Mala Maini, Andre Boonstra, Georg Lauer, An de Creus, Kathleen Whitaker, Sara Ferrando Martinez, Jessica Weber, Emily Gainor, Veronica Miller

A systematic review of limiting antigen avidity enzyme immunoassay for detection of recent HIV-1 infection to expand supported applications. Journal of Virus Eradication. September 2022
JosephKin-On Laua, Nicholas Murdock, Jeffrey Murray, Jessica Justman, Neil Parkin, Veronica Miller

Nomenclature of HBV core protein-targeting antivirals. Nature Reviews Gastroenterology & Hepatology. October 2022
Fabien Zoulim, Adam Zlotnick, Stephanie Buchholz, Eric Donaldson, John Fry, Anuj Gaggar, Jianming Hu, Michael Kann, Oliver Lenz, Kai Lin, Nagraj Mani, Michael Nassal, William Delaney, Su Wang, Gabriel Westman, Veronica Miller & Harry L. A. Janssen

Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project
Neil Parkin, Fei Gao, Eduard Grebe, Amy Cutrell, Moupali Das, Deborah Donnell, Ann Duerr, David V Glidden, James P Hughes, Jeffrey Murray, Michael N Robertson, Joerg Zinserling, Joseph Lau, Veronica Miller; Forum for Collaborative Research Recency Assay Working Group

2021

Association between rectal gonorrhoea and HIV incidence in men who have sex with men: a meta-analysis. Sexually Transmitted Infections. December 2021
Deborah Donnell, Kidist Zewdie, Natasha Ratna, Veronica Miller, John Michael Saunders, O Noel Gill, Valerie Delpech, Hamish Mohammed

Association between rectal gonorrhoea and HIV incidence in men who have sex with men: a meta-analysis
Donnell D, Zewdie K, Ratna N, Miller V, Saunders J, Gill O, Delpech V, Mohammed H. Sexually Transmitted Infections 2022;98:492-496

Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis
Ryan T Anderson, Hannah S J Choi, Oliver Lenz, Marion G Peters, Harry L A Janssen, Poonam Mishra, Eric Donaldson, Gabriel Westman, Stephanie Buchholz, Veronica Miller, Bettina E Hansen

The Use of External Controls in FDA Regulatory Decision Making
Mahta Jahanshahi, Keith Gregg, Gillian Davis, Adora Ndu, Veronica Miller, Jerry Vockley, Cecile Ollivier, Tanja Franolic, Sharon Sakai

Commentary title: COVID-19 research, Africa, and global health
Tinkhani Mbichila, Grace Kumwenda, Ntando Yola, Quarraisha Abdool Karim, Tamar Tchelidze, Joseph Lau, Stephanie Buchholz, Regine Lehnert, Jean-Michel Molina, Kenneth Mayer, Veronica Miller

2020

Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations from the Liver Forum
Oliver Glass, Claudia Filozof, Mazen Noureddin, Mark Berner-Hansen, Elmer Schabel, Stephanie O. Omokaro, Jörn M. Schattenberg, Katherine Barradas, Veronica Miller, Sven Francque, Manal F. Abdelmalek, on behalf of the Liver Forum Standard of Care Working Group

Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations from the Multi-stakeholder Liver Forum
Mazen Noureddin, Jean L. Chan, Katherine Barradas, Lara Dimick-Santos, Elmer Schabel, Stephanie O. Omokaro, Frank A. Anania, Robert P. Myers, Veronica Miller, Arun J. Sanyal, Naga Chalasani, on behalf of the Liver Forum NASH Cirrhosis Working Group

2019

Liver safety assessment in clinical trials of new agents for chronic hepatitis B
Robert J. Fontana, Mark I. Avigan, Harry L. A. Janssen, Arie Regev, Poonam Mishra, Anuj Gaggar, Nathaniel Brown, Cynthia Wat, Patricia Mendez, Ryan T. Anderson, Bruce Given, Veronica Miller, Maria Beumont

Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease
Miriam B. Vos, Lara Dimick-Santos, Ruby Mehta, Stephanie O. Omokaro, Johannes Taminiau, Elmer Schabel, David E. Kleiner, Peter Szitanyi, Piotr Socha, Jeffrey B. Schwimmer, Stephanie Noviello, Debra G. Silberg, Richard Torstenson, Veronica Miller, Joel E. Lavine, on behalf of the Liver Forum Pediatric Working Group

Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
Amanda Cheung, Brent A. Neuschwander-Tetri, David E. Kleiner, Elmer Schabel, Mary Rinella, Stephen Harrison, Vlad Ratziu, Arun J. Sanyal, Rohit Loomba, Sophie Jeannin Megnien, Richard Torstenson, Veronica Miller, on behalf of the Liver Forum Case Definitions Working Group

Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic Hepatitis B Virus
Ryan Taylor Anderson, Seng Gee Lim, Poonam Mishra, Filip Josephson, Eric Donaldson, Bruce Given, Veronica Miller

2018

Can Viral Load be used as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-anaylsis
Yoichiro Natori, Ali Alghamdi, Mahmood Tazari, Veronica Miller, Shahid Husain, Takashi Komatsu, Paul Griffiths, Per Ljungman, Ani Orchanian-Cheff, Deepali Kumar, Atual Humar on behalf of the CMV Consensus Forum

Case definitions for inclusion and analysis of endpoints in clinical trials for NASH through the lens of regulatory science
M. Shadab Siddiqui, Stephen A. Harrison, Manal F. Abdelmalek, Quentin M. Anstee, Pierre Bedossa, Laurent Castera, Lara Dimick-Santos, Scott Friedman, Katherine Greene, David Kleiner, Sophie Megnien, Brent A. Neuschwander-Tetri, Vlad Ratziu, Elmer Schabel,Veronica Miller, Arun J. Sanyal, On behalf of the Liver Forum Case Definitions Working Group

Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials
Roy F. Chemaly, Sunwen Chou, Hermann Einsele, Paul Griffiths, Robin Avery, Raymund R. Razonable, Kathleen M. Mullane, Camille Kotton, Jens Lundgren, Takashi E. Komatsu, Peter Lischka, Filip Josephson, Cameron M. Douglas, Obi Umeh, Veronica Miller, Per Ljungman, the Resistant Definitions Working Group of the Cytomegalovirus Drug Development Forum

2017

Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile
Elena Ivanova Reipold, Philippa Easterbrook, Alessandra Trianni, Nivedha Panneer, Douglas Krakower, Stefano Ongarello, Teri Roberts, Veronica Miller and Claudia Denkinger

The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing
Joseph D. Tucker, Katherine Meyers, John Best, Karyn Kaplan, Razia Pendse, Kevin A. Fenton, Isabelle Andrieux-Meyer, Carmen Figueroa, Pedro Goicochea, Charles Gore, Azumi Ishizaki, Giten Khwairakpam, Veronica Miller, Antons Mozalevskis, Michael Ninburg, Ponsiano Ocama, Rosanna Peeling, Nick Walsh, Massimo G. Colombo and Philippa Easterbrook

Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum
Yuval A. Patel, Joanne C. Imperial, Andrew J. Muir, Quentin M. Anstee, David DeBrota, Lara Dimick-Santos, Claudia Filozof, Ruby Mehta, Arun J. Sanyal, Elmer Schabel, Brent A. Neuschwander-Tetri, Veronica Miller, on behalf of the Liver Forum’s Data Standardization Working Group.

Advancing the Regulatory Path on Hepatitis B Virus Treatment and Curative Research: A Stakeholders Consultation
Liu J, Goicochea P, Block T, Brosgart C, Donaldson EF, Lenz O, Lim SG, Mishra P, Peters MG, Miller, V. Journal of Virus Eradication [Internet]. 2017 Jan [cited 2017 Jan 19]; (issn 2055-66-59 - online).

2016

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials
Per Ljungman Michael Boeckh Hans H. Hirsch Filip Josephson Jens Lundgren Garrett Nichols Andreas Pikis Raymund R. Razonable Veronica Miller Paul D. Griffiths for the Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum

Human cytomegalovirus and transplantation: drug development and regulatory issues
McIntosh M, Hauschild B, and Miller V. Journal of Virus Eradication 2016 July, 2: 143-148

2015

Hepatitis C Virus Drug Resistance-Associated Substitutions: State of the Art Summary
Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Hongmei M, Parkin N, Pilot-Matias T, Miller V. Hepatology 2015 November, 62(5), 1623-1632.

High-priority target product profile for hepatitis C diagnosis in decentralized settings: Report of a consensus meeting
Alessandra Trianni, Nivedha Paneer, and Claudia Denkinger with input from other stakeholders on behalf of meeting participants. 22 April 2015, Vienna, Austria

2014

HIV and HCV Infection in the United States: Whom and How to Test
Panneer N, Lontok E, Branson BM, Teo CG, Dan C, Parker M, Stekler JD, DeMaria A Jr, Miller V. Clin Infect Dis. 2014 May 27. pii: ciu396

Accelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group
Hutchison C, Kwong A, Ray S, Struble K, Swan T, Miller V. Accelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group. Clin Pharmacol Ther. 2014. Jun 25: 1532-6535

2013

The Untold Story of How High-Quality and Low-Cost Drugs Were Incorporated Into PEPFAR.
Quinones-Rivera, A. Annals Of The Forum For Collaborative HIV Research, 15(1). (2013).

Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype-1 Infection Response-Guided Therapy
Lontok E, Mani N, Harrington PR, Miller V. Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype-1 Infection Response-Guided Therapy. Clin Infect Dis. 2013 Jan 29. [Epub ahead of print]

2012

Recommendations for Standardized Nomenclature and Definitions of Viral Response in Trials of Hepatitis C Virus Investigational Agents
Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V; Definitions/Nomenclature Working Group* of the HCV DrAG (HCV Drug Development Advisory Group), under the auspices of the Forum for Collaborative HIV Research. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology. 2012 Dec;56(6):2398-403.

Clinically Relevant HCV Drug Resistance Mutations Figure and Tables (Updated)
HCV Phenotype Working Group, HCV Drug Development Advisory Group. Ann Forum Collab HIV Res. Volume 14 (2): 2012; 1-10.

Novel Clinical Trial Designs for the Development of New Antiretroviral Agents
Mani N, Murray J, Gulick RM, Josephson F, Miller V, Miele P, Strobos J, Struble KA. Novel clinical trial designs for the development of new antiretroviral agents. AIDS. 26(8):899-907, May 15, 2012.

Adverse Outcome Analyses of Observational Data: Assessing Cardiovascular Risk in HIV Disease
Triant V, Josephson F, Rochester CG, Althoff KN, Marcus K, Munk R, Cooper C, D'Agostino RB, Costagliola D, Sabin CA, Williams PL, Hughes S, Post WS, Chandra-Strobos N, Guaraldi G, Young SS, Obenchain R, Bedimo R, Miller V, Strobos J. Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease. Clin Infect Dis. 2012 Feb 1;54(3):408-13

2011

Safety Considerations in the Prevention of Transmission of HIV by Pre-Exposure Prophylaxis (or "PrEP")
Jur Strobos, Benjamin C Hauschild, Veronica Miller
Ann Forum Collab HIV Res: Vol 13, No 5. Nov. 28, 201.

Municipal Scale-up of HIV Testing in the United States: Current Status, Challenges and Opportunities from a Multi-Stakeholder Perspective
Benjamin C Hauschild, Veronica Miller, Jur Strobos
Ann Forum Collab HIV Res: Vol 13, No 4
Nov. 7, 2011

Recommendations from a Research Consultation to Inform the Next Generation of HIV Prevention Messaging for Men Who Have Sex with Men (MSM)
Jennifer Uhrig, Megan A Lewis, George Ayala,, Jo Ellen Stryker
Ann Forum Collab HIV Res
Oct. 3, 2011

Global Pharmacovigilance for Antiretroviral Drugs: Overcoming Contrasting Priorities
Bakare N, Edwards IR, Stergachis A, Pal S, Holmes CB, Lindquist M, et al. Global pharmacovigilance for antiretroviral drugs: overcoming contrasting properties. PLoS Med 2011 Jul;8(7):e1001054.Epub 2011 Jul 5.

Recognizing Leadership, Courage and Hands-On Engagement: Relearning Lessons 30 Years Later
Veronica Miller
Ann Forum Collab HIV Res
Mar. 29, 2011

Presentation of the C. Everett Koop HIV/AIDS Health Leadership Award to VADM C. Everett Koop, MD, SCD, 13th U.S. Surgeon General
Anthony S. Fauci
Ann Forum Collab HIV Res
Mar. 29, 2011

The Early Days of AIDS, As I Remember Them
C. Everett Koop
Ann Forum Collab HIV Res
Mar. 29, 2011

Sequence and Phenotypic Analysis for Resistance Monitoring in Hepatitis C Virus Drug Development: Recommendations from the HCV DRAG
Ann D. Kwong, Isabel Najera, Jill Bechtel, Steven Bowden, Joseph Fitzgibbon, Patrick Harrington, Dale Kempf, Tara L. Kieffer, Diana Koletzki, George Kukolj, Sharlene Lim, Tami Pilot-Matias, Kai Lin, Nina Mani, Hongmei Mo, Jules O'Rear, Michael Otto, Neil Parkin, Jean-Michel Pawlotsky, Christos Petropoulos, Gaston Picchio, Robert Ralston, Jacqueline D. Reeves, Robert T. Schooley, Scott Seiwert, David Standring, Lieven Stuyver, James Sullivan, Veronica Miller, Forum for Collaborative HIV Research, HCV Drug Development Advisory Group (HCV DrAG), Sequence Analysis Working Group (SAWG), Phenotype Analysis Working Group (PAWG). Sequence and phenotypic analysis for resistance monitoring in hepatitis c virus drug development: recommendations from the HCV DrAG. Gastroenterology. 2011 Mar 12;140(3):755-60

HIV Clinic Capacity and Medical Workforce Challenges: Results of a Survey of Ryan White Part C-funded Programs
Benjamin C. Hauschild, Andrea Weddle, Jenny K. Tegelvik, Christine Lubinski, Veronica Miller, Michael S. Saag
Ann Forum Collab HIV Res
Jan. 21, 2011

2010

2010 National Summit on HIV Diagnosis, Prevention and Access to Care. November 17, 2010

2009

The Forum for Collaborative HIV Research: A Model for an Integrated and Inclusive Approach to Clinical Research and Drug Development
Miller V. The forum for collaborative HIV research: a model for an integrated and inclusive approach to clinical research and drug development. Clin Pharmacol Ther. 2009 Sep 1;86(3):332-5. Sep. 1, 2009

Evaluation of Impact of Adult Male Circumcision Programs on HIV Incidence and Prevalence: Current Research, Gaps in Knowledge and Recommendations for Additional Research
Sarah Kim, Shrimant Mishra, Veronica Miller
Ann Forum Collab HIV Res
Apr. 23, 2009

Metrics and Evaluation Measures for Monitoring the Implementation of Routine HIV Testing in the U.S.
Benjamin Hauschild, Linda Onaga
Ann Forum Collab HIV Res
Apr. 23, 2009

2008

HIV Clinical Trial Design for Antiretroviral Development: Moving Forward
Chan-Tack KM, Struble KA, Morgensztejn N, Murray JS, Cheng B, Weller I, Miller V. HIV clinical trial design for antiretroviral development: moving forward. AIDS. 2008 Nov 30;22(18):2419-27.

Opt-Out Testing for Human Immunodeficiency Virus in the United States: Progress and Challenges
Bartlett JG, Branson BM, Fenton K, Hauschild BC, Miller V, Mayer KH. Opt-out testing for human immunodeficiency virus in the united states: progress and challenges. JAMA. 2008 Aug 27;300(8):945-951.

Initiatives for Developing and Comparing Genotype Interpretation Systems Step 1: External Validation of Existing Rules-Based Algorithm for Abacavir and ddI Evaluated on Virological Response
Assoumou L, Brun-V zinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, DeGruttola V, Miller V, Costagliola D. Initiatives for developing and comparing genotype interpretation systems step 1: external validation of existing rules-based algorithm for abacavir and ddI evaluated on virological response. Journal of Infectious Diseases. 2008 Aug 15;198(4):470-80.

Research Needs and Challenges in the Development of HIV Diagnostic and Treatment Monitoring Tests for Use in Resource-Limited Settings
Cheng B, Landay A, Miller V. Research needs and challenges in the development of HIV diagnostic and treatment monitoring tests for use in resource-limited settings. Curr Opin HIV AIDS;2008 Jul 1;3(4):495-503.

Meeting the Demand for Male Circumcision
Nyasha Bakare, Veronica Miller
Ann Forum Collab HIV Res
Jun. 17, 2008

ARV Drugs, Adverse Events, Case Definition, Grading, Laboratory Diagnosis and Treatment Monitoring
Veronica Miller
Ann Forum Collab HIV Res
Jun. 17, 2008

2007

HIV-TB Co-Infection: Meeting the Challenge
Nyasha Bakare, Veronica Miller
Ann Forum Collab HIV Res
Nov. 2, 2007

Rethinking the Approach to Expanded Access Programs
Eric Zechman, Ben Cheng, Veronica Miller
Ann Forum Collab HIV Res
Jun. 14, 2007

Collaborative Approaches to HIV Drug Development: Planning for Long-Term Monitoring of Safety in CCR5 Antagonist Development
John Fry, Johanna Bogulavsky Grossman, Veronica Miller
Ann Forum Collab HIV Res
Apr. 24, 2007

A New Era for HIV Prevention?
Chris Collins, Meagan Lyon, Veronica Miller
Ann Forum Collab HIV Res
Feb. 1, 2007

HIV and TB in the Context of Universal Access: What is Working and What is not? Meeting Report
The World Health Organization
hivforum.org
2007

2006

Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
Khalsa J, Vocci F, Altice F, Fiellin D, Miller V. Buprenorphine and HIV primary care: new opportunities for integrated treatment. Clin Infect Dis. 2006 Dec 15;43(4):169-72.

Pediatric HIV Diagnosis & Laboratory Monitoring
Veronica Miller
Ann Forum Collab HIV Res
Nov. 1, 2006

Racial Ethnic Minority Issues in HIV/AIDS
Craig Hunter, Veronica Miller
Ann Forum Collab HIV Res
Nov. 1, 2006

HIV-1 Viral Load Assays for Resource-Limited Settings
Fiscus SA, Cheng B, Crowe SM, Demeter L, Jennings C, et al. (2006) HIV-1 viral load assays for resource-limited settings. PLoS Med 3(10): e417. doi:10.1371/journal.pmed.0030417

International Public Health Dialogue on HIV Testing and Counselling Report
Public Health Agency of Canada
hivforum.org
Aug. 17, 2006

2005

Meeting Summary and Report: Developing and HIV Health Services Research Agenda
Jeffrey Levi, Veronica Miller
Ann Forum Collab HIV Res
Jun. 1, 2005

Antiretroviral Therapies for Treatment Experienced Patients: Current Status and Research Challenges
Struble KA, Murray JS, Cheng B, Gegeny T, Miller V, Gulick RM. Antiretroviral therapies for treatment experienced patients: current status and research challenges. AIDS. 2005 May 20;19(8):747-56.

Regulatory Considerations for the Treatment of Lipodystrophy
Sally Snyder, Ben Cheng, Veronica Miller
Ann Forum Collab HIV Res
May 1, 2005

Buprenorphine and Primary HIV Care
Jeanine Warden, Craig Hunter, Veronica Miller
Ann Forum Collab HIV Res
Mar. 2005

2004

Roundtable Report: Importance of Antiretroviral Drug Levels in Sanctuary Sites and Viral Reservoirs
Reddy YS, Kashuba A, Gerber J, Miller V. Roundtable report: importance of antiretroviral drug levels in sanctuary sites and viral reservoirs. AIDS Research and Human Retroviruses. 2004 Jul 5;19(3):167-76.

2003

Quality of HIV Care - Closing the Gap: A Report on the Findings from the Quality of HIV Care Project
Veronica Miller
Ann Forum Collab HIV Res
Dec. 4, 2003

Monitoring of long-term toxicities of HIV treatments: an international perspective
Greg Bisson, Robert Gross, Veronica Miller, Ian Weller, Alexander Walker, on behalf of the writing group
AIDS
Nov. 21, 2003

Protein Binding in Antiretroviral Therapies
Marta Boffito, David J. Back, Terrence F. Blaschke, Malcolm Rowland, Richard J. Bertz, John G. Gerber, and Veronica Miller on behalf of the roundtable participants
AIDS Research and Human Retroviruses
Nov. 9, 2003

QA/QC of CD4 and Viral Load Assays in the Resource-Limited Setting
Kevin Moody, Veronica Miller
Ann Forum Collab HIV Res
Oct. 30, 2003

Cardiovascular Risk in HIV Infection and Treatment
Mark Mascolini, Veronica Miller
Ann Forum Collab HIV Res
May 22, 2003

Forum for Collaborative HIV Research Summary of Executive Committee Retreat
Veronica Miller
Ann Forum Collab HIV Res
Mar. 19, 2003

STI Roundtable Discussion: Moving the Agenda Forward
Richard Jefferys, Veronica Miller
Ann Forum Collab HIV Res
Feb. 8, 2003

2002

What Defines HIV Lipodystrophy?
Mark Mascolini, Veronica Miller
Ann Forum Collab HIV Res
Sep. 23, 2002

Report of the Workshop: Sex and Gender Issues in HIV Disease
Veronica Miller
Ann Forum Collab HIV Res
Sep. 4, 2002

Cheaper HIV Drugs for Poor Nations Bring a New Challenge: Monitoring Treatment
Joan Stephenson
JAMA
Jul. 10, 2002

Transfer of HIV Diagnostic and Monitoring Technologies into Resource-Poor Settings
Le Transfert des Technologies pour le Diagnostic et le Monitoring de l'Infection VIH dans les Pays en Développement (French Version)
Mark Mascolini, Veronica Miller
Ann Forum Collab HIV Res
May 2002

Report from the 3rd International STI Workshop
Richard Jefferys, Veronica Miller
Ann Forum Collab HIV Res
Apr. 22, 2002

2001

Linkage and Integration of HIV Testing, Prevention, and Care
John Palen, Veronica Miller
Ann Forum Collab HIV Res
Oct. 2001

Linking HIV Testing, Prevention and Care
Helen Schietinger
Ann Forum Collab HIV Res
Sep. 21, 2001

Examining the Risk and Benefits of Directly Observed Therapy for Treatment of HIV Disease
Karen Eddelman
Ann Forum Collab HIV Res
Apr. 17, 2001

Immunologic Markers to Evaluate Immune-Based Therapies in HIV Disease Meeting Reporting
Mark Mascolini
Ann Forum Collab HIV Res
Feb. 6, 2001

Structured Treatment Interruptions Workshop Summary
Veronica Miller
Ann Forum Collab HIV Res
Jan. 31, 2001

Report of the DHHS Working Group on Dissemination of HIV Treatment Information
Veronica Miller
Ann Forum Collab HIV Res
2001

2000

Immune-Based Therapies: A Review of Clinical Endpoints Used in Trials of Selected Immunologic Agents
Karen Eddleman, Veronica Miller
Ann Forum Collab HIV Res
Dec. 1, 2000

Immune-Based Therapies and HIV Disease
Alan Landay, June Bray, Veronica Miller
Ann Forum Collab HIV Res
Dec. 7, 2000

Bone Metabolism and HIV Disease Meeting Report
Lawrence Raisz, Jane Aubin, Veronica Miller
Ann Forum Collab HIV Res
Aug. 29, 2000

Mitochondrial Toxicity and HIV Disease Meeting Report
Kees Brinkman, William Copeland, Veronica Miller
Ann Forum Collab HIV Res
Jun. 5, 2000

Meeting on Drug Interaction Research in HIV Disease
David Barr, Veronica Miller
Ann Forum Collab HIV Res
Apr. 1, 2000

1999

Adherence to HIV Therapy: Building a Bridge to Success
DHHS Health Resources and Services Administration (HRSA) and The Forum for Collaborative HIV Research in collaboration with NIH Office of AIDS Research
hivforum.org
Nov. 15, 1999

Adherence to Highly Active Antiretroviral Therapy (HAART) Among Individuals
David Barr, Robert D. Webster
hivforum.org
Nov. 15, 1999

The Potential of Patient Outcomes Research
Helen Schietinger
Ann Forum Collab HIV Res
Sep. 1, 1999

Simplifying Antiretroviral Treatment Regimens-A Summary of Current Research
Dave Gilden
hivforum.org
Jun. 1, 1999

Failure of Initial Antiretroviral Treatment Regimens
David Gilden
Ann Forum Collab HIV Res
Jan. 1999

The Challenges of Clinical Trial Design in Assessing the Effects of Anti-HIV Therapy in Heavily Pre-Treated Patients
David Barr
Ann Forum Collab HIV Res
1999